Integral Diagnostics Limited
IDX.ASXHealth Care
Provider of medical imaging services across Australia and New Zealand.
Market Data
$2.170
+0.0%$790.9M
57.9x
$0.037
3.36%
-0.1%
Latest Earnings
FY26 Half Year Results App4D and Interim Report
24 February 2026
Integral Diagnostics reported strong HY26 results driven by the Capitol Health acquisition, with revenue up 55.6% to $393.5M and EBITDA surging 91.4% to $67.1M. The company achieved solid organic growth of 6.9% on a constant currency basis and declared an interim dividend of 3.3 cents, up from 2.5 cents previously. Integration synergies from the Capitol merger are exceeding expectations at $14M+ annually. Key points: Capitol Health merger synergies significantly exceeding initial expectations at $14M+ annually vs $10M+ originally expected; Strong organic revenue growth of 6.9% on constant currency basis excluding closed/sold sites; Improved Group Operating EBITDA margin of 20.6%, up 230 bps vs HY25
Recent Announcements
Ceasing to be a substantial holder
Australian Retirement Trust Pty LTD ATF Australian Retirement Trust ceased to be a substantial holder.
Becoming a substantial holder
controlled entities named in the list of 4 pages annexed to this notice and marked A (Daiichi Controlled Entities) became a substantial holder.
Becoming a substantial holder
Australian Retirement Trust Pty LTD ATF Australian Retirement Trust became a substantial holder (5.016%).
FY26 Half Year Results Investor Presentation
IDX delivered strong 1H FY26 results with revenue growing 55.6% to $393.5M including six months contribution from Capitol merger. Operating EBITDA increased 75.6% to $81.1M with margin expansion of 230bps to 20.6%, while synergies of $14M+ exceeded initial expectations. The company is well positioned for continued growth from MRI deregulation and lung cancer screening programs. Key points: Strong revenue growth of 55.6% to $393.5M including Capitol contribution; Operating EBITDA margin improved 230bps to 20.6% with 75.6% growth to $81.1M; Capitol merger synergies of $14M+ exceeded initial $10M expectations
FY26 Half Year Results Media Release
Integral Diagnostics delivered strong 1H FY26 results with revenue up 55.6% to $393.5M and Operating EBITDA growing 75.6% to $81.1M at an improved margin of 20.6%. The Capitol Health merger integration is exceeding expectations with $14.0M+ in annual synergies realized versus initial expectations of $10.0M. The company maintained strong guidance for FY26 Operating EBITDA margin of ~21.0% with continued revenue growth expected. Key points: Strong Operating EBITDA margin improvement to 20.6%, up 230 basis points; Capitol Health merger integration exceeding expectations with $14.0M+ annual synergies vs $10.0M initial target; Strong balance sheet with reduced leverage to 2.5x Net Debt/EBITDA ratio
FY26 Half Year Results App4D and Interim Report
Integral Diagnostics reported strong HY26 results driven by the Capitol Health acquisition, with revenue up 55.6% to $393.5M and EBITDA surging 91.4% to $67.1M. The company achieved solid organic growth of 6.9% on a constant currency basis and declared an interim dividend of 3.3 cents, up from 2.5 cents previously. Integration synergies from the Capitol merger are exceeding expectations at $14M+ annually. Key points: Capitol Health merger synergies significantly exceeding initial expectations at $14M+ annually vs $10M+ originally expected; Strong organic revenue growth of 6.9% on constant currency basis excluding closed/sold sites; Improved Group Operating EBITDA margin of 20.6%, up 230 bps vs HY25
Get real-time alerts for IDX
Receive AI-powered earnings summaries and instant notifications when Integral Diagnostics Limited releases results.
Register Free